This study is designed to assess the correlation of the functional translational biomarker P300 latency and change in ADAS-Cog11 induced by ATH-1017 therapy, over 26-week randomized, double-blind treatment.
This study is designed to evaluate treatment effects of fosgonimeton (ATH-1017) in mild to moderate Alzheimer's subjects with a randomized treatment duration of 26-weeks.